Efficient Synthesis of a Chiral Precursor for Angiotensin-Converting Enzyme (ACE) Inhibitors in High Space-Time Yield by a New Reductase without External Cofactors

2012 ◽  
Vol 14 (8) ◽  
pp. 1982-1985 ◽  
Author(s):  
Nai-Dong Shen ◽  
Yan Ni ◽  
Hong-Min Ma ◽  
Li-Juan Wang ◽  
Chun-Xiu Li ◽  
...  
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Ace Inhibitors ◽  
Space Time ◽  
Converting Enzyme ◽  
Efficient Synthesis ◽  
High Space ◽  
Space Time Yield

scholarly journals Efficient synthesis of Ibrutinib chiral intermediate in high space-time yield by recombinant E. coli co-expressing alcohol dehydrogenase and glucose dehydrogenase

RSC Advances ◽  
2019 ◽  
Vol 9 (4) ◽  
pp. 2325-2331 ◽  
Author(s):  
Yitong Chen ◽  
Baodi Ma ◽  
Songshuang Cao ◽  
Xiaomei Wu ◽  
Yi Xu
Keyword(s):  
Alcohol Dehydrogenase ◽  
Glucose Dehydrogenase ◽  
Space Time ◽  
Optically Active ◽  
Efficient Synthesis ◽  
E Coli ◽  
Efficient Process ◽  
High Space ◽  
Space Time Yield

A simple and efficient process for the synthesis of optically active (S)-N-boc-3-hydroxy piperidine was developed using the “designer cells” co-expressing alcohol dehydrogenase and glucose dehydrogenase.

Efficient synthesis of a statin precursor in high space-time yield by a new aldehyde-tolerant aldolase identified from Lactobacillus brevis

2015 ◽  
Vol 5 (8) ◽  
pp. 4048-4054 ◽  
Author(s):  
Xue-Cheng Jiao ◽  
Jiang Pan ◽  
Guo-Chao Xu ◽  
Xu-Dong Kong ◽  
Qi Chen ◽  
...  
Keyword(s):  
High Activity ◽  
Lactobacillus Brevis ◽  
Space Time ◽  
High Tolerance ◽  
Efficient Synthesis ◽  
High Space ◽  
Space Time Yield

A novel 2-deoxyribose-5-phosphate aldolase (LbDERA) was identified from Lactobacillus brevis, with high activity, excellent thermostability and high tolerance against aldehyde substrates.

scholarly journals A clinical dose of angiotensin-converting enzyme (ACE) inhibitor and heterozygous ACE deletion exacerbate Alzheimer's disease pathology in mice

2019 ◽  
Vol 294 (25) ◽  
pp. 9760-9770 ◽  
Author(s):  
Shuyu Liu ◽  
Fujiko Ando ◽  
Yu Fujita ◽  
Junjun Liu ◽  
Tomoji Maeda ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Angiotensin Converting Enzyme ◽  
Amyloid Precursor Protein ◽  
Ace Inhibitors ◽  
Ace Inhibitor ◽  
Precursor Protein ◽  
Causative Role ◽  
Converting Enzyme ◽  
Clinical Dose

Inhibition of angiotensin-converting enzyme (ACE) is a strategy used worldwide for managing hypertension. In addition to converting angiotensin I to angiotensin II, ACE also converts neurotoxic β-amyloid protein 42 (Aβ42) to Aβ40. Because of its neurotoxicity, Aβ42 is believed to play a causative role in the development of Alzheimer's disease (AD), whereas Aβ40 has neuroprotective effects against Aβ42 aggregation and also against metal-induced oxidative damage. Whether ACE inhibition enhances Aβ42 aggregation or impairs human cognitive ability are very important issues for preventing AD onset and for optimal hypertension management. In an 8-year longitudinal study, we found here that the mean intelligence quotient of male, but not female, hypertensive patients taking ACE inhibitors declined more rapidly than that of others taking no ACE inhibitors. Moreover, the sera of all AD patients exhibited a decrease in Aβ42-to-Aβ40–converting activity compared with sera from age-matched healthy individuals. Using human amyloid precursor protein transgenic mice, we found that a clinical dose of an ACE inhibitor was sufficient to increase brain amyloid deposition. We also generated human amyloid precursor protein/ACE+/− mice and found that a decrease in ACE levels promoted Aβ42 deposition and increased the number of apoptotic neurons. These results suggest that inhibition of ACE activity is a risk factor for impaired human cognition and for triggering AD onset.

Kefir peptide (Kef-1) as an emerging approach for the treatment of oxidative stress and inflammation in 2K1C mice

2022 ◽  
Author(s):  
Rafaela Aires ◽  
Fernanda Gobbi Amorim ◽  
Larissa Zambom Côco ◽  
Amanda Pompermayer da Conceição ◽  
Tadeu Ériton Caliman Zanardo ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Angiotensin Converting Enzyme ◽  
Ace Inhibitors ◽  
Bioactive Molecules ◽  
Converting Enzyme ◽  
The Rich ◽  
Potential Use

The benefits of Kefir consumption are due, in part, to the rich composition of bioactive molecules released from fermentation. Angiotensin-converting enzyme (ACE) inhibitors are bioactive molecules with potential use in...

Synthesis of pure and uniform nano-sized TS-1 crystal with high titanium content and high space-time yield

2021 ◽  
Author(s):  
Lejian Zhang ◽  
Xiaoxiao Zhu ◽  
Xinping Wang ◽  
Chuan Shi
Keyword(s):  
Selective Oxidation ◽  
Cost Efficiency ◽  
Environmental Issues ◽  
Titanium Content ◽  
Space Time ◽  
Titanium Silicalite ◽  
Oxidation Reactions ◽  
High Space ◽  
Space Time Yield ◽  
Selective Oxidation Reactions

Anatase-free titanium silicalite-1 (TS-1) zeolite with high framework titanium content is highly required for catalysing selective oxidation reactions, while its synthesis generally suffers from cost, efficiency and environmental issues. Herein,...

scholarly journals Normal-phase thin-layer chromatography of some angiotensin converting enzyme (ACE) inhibitors and their metabolites

2009 ◽  
Vol 74 (6) ◽  
pp. 677-688 ◽  
Author(s):  
Jadranka Odovic ◽  
Mirjana Aleksic ◽  
Biljana Stojimirovic ◽  
Dusanka Milojkovic-Opsenica ◽  
Zivoslav Tesic
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Thin Layer ◽  
Thin Layer Chromatography ◽  
Ace Inhibitors ◽  
Reversed Phase ◽  
Normal Phase ◽  
Converting Enzyme ◽  
Reversed Phase Chromatography ◽  
Aqueous Solvent ◽  
Layer Chromatography

The separation and chromatographic behaviour of five ACE (angiotensin converting enzyme) inhibitors and their four active metabolites were investigated by normal-phase thin-layer chromatography on silica using several mono- and binary non-aqueous solvent systems. The linear relationship between the RM values and the composition of employed mobile phase was obtained. The hydrophobicity parameters 0M R and C0 were determined from the regression data of the plots, analogous to reversed-phase chromatography. The chromatographically obtained hydrophobicity parameters were correlated with the calculated log P values. The current results were correlated with the lipophilicity of the studied ACE inhibitors and their metabolites, previously estimated by reversed-phase chromatography.

scholarly journals The effect of angiotensin-converting enzyme inhibitors on clinical outcomes in patients with ischemic cardiomyopathy and midrange ejection fraction: a post hoc subgroup analysis from the PEACE trial

2018 ◽  
Vol 12 (12) ◽  
pp. 351-359 ◽  
Author(s):  
Talal Alzahrani ◽  
John Tiu ◽  
Gurusher Panjrath ◽  
Allen Solomon
Keyword(s):  
Ejection Fraction ◽  
Angiotensin Converting Enzyme ◽  
Clinical Outcomes ◽  
Ace Inhibitors ◽  
Subgroup Analysis ◽  
Ischemic Cardiomyopathy ◽  
Angiotensin Converting Enzyme Inhibition ◽  
Converting Enzyme ◽  
All Cause Mortality ◽  
Post Hoc

Background: There have been significant advances in the treatment of patients with cardiomyopathy with reduced ejection fraction (EF < 40%). However, there is a dearth of information in the treatment of patients with cardiomyopathy and midrange EF (40–50%). Current guidelines state to treat these patients similarly to patients with cardiomyopathy and preserved EF. Data from the Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) trial were used to elucidate whether angiotensin-converting enzyme (ACE) inhibitors improve clinical outcomes in patients with ischemic cardiomyopathy and midrange EF. Methods: A post hoc subgroup analysis of the PEACE trial was conducted to evaluate the effect of ACE inhibitors in a subgroup of patients with ischemic cardiomyopathy and midrange EF (40–50%). A Chi-square test and a Student‘s t-test were used to examine and compare the binary and continuous variables of baseline characteristics and outcomes between experimental and comparison groups. Results: We studied a subgroup of patients from the PEACE trial with ischemic cardiomyopathy and midrange EF ( n = 2512 of 8290 total patients). Patients were assigned to either the interventional group ( n = 1247) or the placebo group ( n = 1265). There were no significant differences in baseline demographic and health characteristics between the two groups. During a total of 7 years (mean 4.7 years) of follow up, the risk of composite outcomes [all-cause mortality, nonfatal myocardial infarction, and stroke; relative risk (RR) 0.79, 95% confidence interval (CI) 0.63–0.98; p = 0.03] and all-cause mortality (RR 0.85, 95% CI 0.73–0.99; p = 0.03) was reduced in patients treated with trandolapril. Conclusion: This study revealed the benefit of ACE inhibitors among patients with ischemic cardiomyopathy and midrange EF.

Sign in / Sign up

Export Citation Format

Share Document